Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019
Go back to Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019| (NASDAQ: RYTM) | Delayed: 98.34 -0.68 (0.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $99.02 | 52 Week High | $ | |||
| Open | $99.36 | 52 Week Low | $ | |||
| Day High | $99.36 | P/E | N/A | |||
| Day Low | $96.88 | EPS | $ | |||
| Volume | 421,635 | |||||
